First Administration of the Fc-Attenuated Anti-β Amyloid Antibody GSK933776 to Patients with Mild Alzheimer's Disease: A Randomized, Placebo-Controlled Study.

Research output: Contribution to journalArticle

Abstract

To assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of the Fc-inactivated anti-β amyloid (Aβ) monoclonal antibody (mAb) GSK933776 in patients with mild Alzheimer's disease (AD) or mild cognitive impairment (MCI).

Details

Authors
  • Niels Andreasen
  • Monica Simeoni
  • Henrik Östlund
  • Pia I Lisjo
  • Tormod Fladby
  • Amy E Loercher
  • Gerard J Byrne
  • Frances Murray
  • Paul T Scott-Stevens
  • Anders Wallin
  • Yinghua Y Zhang
  • Lena H Bronge
  • Henrik Zetterberg
  • Agneta K Nordberg
  • Astrid J Yeo
  • Shahid A Khan
  • Jan Hilpert
  • Prafull C Mistry
Organisations
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Neurology
Original languageEnglish
Article numbere0098153
JournalPLoS ONE
Volume10
Issue number3
Publication statusPublished - 2015
Publication categoryResearch
Peer-reviewedYes